Next Article in Journal
Challenges and Perspectives of Standard Therapy and Drug Development in High-Grade Gliomas
Next Article in Special Issue
Peptide–Protein Interactions: From Drug Design to Supramolecular Biomaterials
Previous Article in Journal
Replacement of the Common Chromium Source CrCl3(thf)3 with Well-Defined [CrCl2(μ-Cl)(thf)2]2
Previous Article in Special Issue
Diketopiperazine-Based, Flexible Tadalafil Analogues: Synthesis, Crystal Structures and Biological Activity Profile
Open AccessArticle

The Wound Healing Peptide, AES16-2M, Ameliorates Atopic Dermatitis In Vivo

1
Korea University Kine Sciences Research Institute, Kine Sciences, 525, Seolleung-ro, Gangnam-gu, Seoul 06149, Korea
2
Division of Life Sciences, College of Life Sciences and Biotechnology, Korea University, 5-ga, Anam-dong, Seongbuk-gu, Seoul 02841, Korea
3
Institute of Convergence Science, Korea University, 5-ga, Anam-ro 145, Seongbuk-gu, Seoul 02841, Korea
*
Author to whom correspondence should be addressed.
Academic Editor: Joanna Bojarska
Molecules 2021, 26(4), 1168; https://doi.org/10.3390/molecules26041168
Received: 28 December 2020 / Revised: 18 February 2021 / Accepted: 18 February 2021 / Published: 22 February 2021
(This article belongs to the Special Issue Advances in Research of Short Peptides)
Peptide materials have recently been considered for use in various industrial fields. Because of their efficacy, safety, and low cost, therapeutic peptides are studied for various diseases, including atopic dermatitis (AD). AD is a common inflammatory skin disease impairing the patient’s quality of life. Various therapies, such as treatments with corticosteroids, calcineurin inhibitors, and antibody drugs, have been applied, but numerous side effects have been reported, including skin atrophy, burning, and infection. In the case of antibody drugs, immunogenicity against the drugs can be a problem. To overcome these side effects, small peptides are considered therapeutic agents. We previously identified the small wound healing peptide AES16-2M with a sequence of REGRT, and examined its effects on AD in this study. Interestingly, the administration of AES16-2M downregulated the AD disease score, ear thickness, serum IgE, and thymic stromal lymphopoietin (TSLP) in AD mice. The thickness of the epidermal layer was also improved by AES16-2M treatment. In addition, quantities of IL-4-, IL-13-, and IL-17-producing CD4 T cells from peripheral lymph nodes and spleens were reduced by injection of AES16-2M. Furthermore, the expression of TSLP was significantly reduced in AES16-2M-treated human keratinocytes. Therefore, these results suggest that AES16-2M can be a novel candidate for AD treatment. View Full-Text
Keywords: short peptide; AES16-2M; atopic dermatitis short peptide; AES16-2M; atopic dermatitis
Show Figures

Figure 1

MDPI and ACS Style

Kim, M.S.; Song, J.; Park, S.; Kim, T.S.; Park, H.J.; Cho, D. The Wound Healing Peptide, AES16-2M, Ameliorates Atopic Dermatitis In Vivo. Molecules 2021, 26, 1168. https://doi.org/10.3390/molecules26041168

AMA Style

Kim MS, Song J, Park S, Kim TS, Park HJ, Cho D. The Wound Healing Peptide, AES16-2M, Ameliorates Atopic Dermatitis In Vivo. Molecules. 2021; 26(4):1168. https://doi.org/10.3390/molecules26041168

Chicago/Turabian Style

Kim, Myun S.; Song, Jisun; Park, Sunyoung; Kim, Tae S.; Park, Hyun J.; Cho, Daeho. 2021. "The Wound Healing Peptide, AES16-2M, Ameliorates Atopic Dermatitis In Vivo" Molecules 26, no. 4: 1168. https://doi.org/10.3390/molecules26041168

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop